Clinical trials: Paroxysmal Supraventricular Tachycardia
Paroxysmal Supraventricular Tachycardia
Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302
The primary objective of this study is to evaluate the safety of etripamil nasal spray (NS) 70 mg when self-administered by patients with an episode of Paroxysmal Supraventricular Tachycardia in an outpatient setting (i.e.…
- Trial name
- NCT03635996
- Testing
- Etripamil NS 70 mg, Aptar Pharma Nasal Spray Bidose System
- Where
- 34 sites in United States, Canada
- Volunteers
- 169 people
- Sponsor
- Milestone Pharmaceuticals Inc.
Paroxysmal Supraventricular Tachycardia
Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).
This was a three-part, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etripamil nasal spray (NS) self-administered by participants who experienced an episode of paroxysmal…
- Trial name
- NODE-301 (NCT03464019)
- Testing
- Etripamil, Etripamil Test Dose
- Where
- 161 sites in United States, Belgium and 7 more
- Volunteers
- 1,097 people
- Sponsor
- Milestone Pharmaceuticals Inc.
Paroxysmal Supraventricular Tachycardia
Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303
NODE-303 was a multi-center, open label study to evaluate the safety of etripamil NS in participants with Paroxysmal Supraventricular Tachycardia (PSVT).
- Trial name
- NCT04072835
- Testing
- Etripamil NS
- Where
- 124 sites in United States, Argentina and 3 more
- Volunteers
- 1,116 people
- Sponsor
- Milestone Pharmaceuticals Inc.
Paroxysmal Supraventricular Tachycardia (PSVT)
Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm
The primary objective of this study is to demonstrate the superiority of at least 1 dose of intranasal (IN) MSP-2017 (Etripamil) over placebo in terminating PSVT induced in an electrophysiology (EP) laboratory.
- Trial name
- NODE-1 (NCT02296190)
- Testing
- Etripamil
- Where
- 30 sites in United States, Canada
- Volunteers
- 199 people
- Sponsor
- Milestone Pharmaceuticals Inc.